Tandem Diabetes Care (TNDM) Depreciation & Amortization (CF) (2013 - 2026)

Tandem Diabetes Care has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 4.48% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $17.9 million (up 5.83% YoY), and the FY2025 full-year result was $17.7 million, up 6.38% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $4.5 million, roughly flat from $4.5 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $4.5 million in Q1 2026, with the low at $3.4 million in Q1 2023.
• Historically, Depreciation & Amortization (CF) has averaged $4.0 million across 5 years, with a median of $4.1 million in 2024.
• The largest YoY upside for Depreciation & Amortization (CF) was 20.04% in 2023 against a maximum downside of 6.39% in 2023.
• Tandem Diabetes Care's Depreciation & Amortization (CF) stood at $3.6 million in 2022, then climbed by 10.71% to $4.0 million in 2023, then grew by 5.31% to $4.2 million in 2024, then rose by 5.89% to $4.5 million in 2025, then increased by 0.2% to $4.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $4.5 million (Q1 2026), $4.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.